Jeff T. Hutchins
Keine laufenden Positionen mehr
Profil
Jeff T.
Hutchins worked as a Director of Monoclonal Antibody Development at Glaxo Wellcome, Inc. from 1991 to 2007.
He then worked as a Vice President of Preclinical Research at Avid Bioservices, Inc. from 2012 to 2016.
He also held the position of Vice President of Preclinical Development at Inhibitex LLC.
Later, he worked as the Chief Operating & Scientific Officer at Scorpius Holdings, Inc. from 2017 to 2020.
He also worked as a Senior Vice President at Pelican Therapeutics, Inc. Dr. Hutchins received his undergraduate degree from Oral Roberts University and his doctorate from The University of Texas Health Science Center at Houston.
Ehemalige bekannte Positionen von Jeff T. Hutchins
| Unternehmen | Position | Ende |
|---|---|---|
| SCORPIUS HOLDINGS, INC. | Geschäftsführer | 31.12.2020 |
| AVID BIOSERVICES, INC. | Corporate Officer/Principal | 01.12.2016 |
| Glaxo Wellcome, Inc. | Corporate Officer/Principal | 01.01.2007 |
Pelican Therapeutics, Inc.
 Pelican Therapeutics, Inc. Hospital/Nursing ManagementHealth Services Pelican Therapeutics, Inc. operates as an immuno-oncology company. It develops biological agents that represents the next generation of tumor necrosis factor (TNF) based immunotherapy. The company was founded by Jeffrey Wolf and Josiah C. Hornblower on March 6, 2017 and is headquartered in Dallas, TX. | Corporate Officer/Principal | - |
Inhibitex LLC
 Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | Corporate Officer/Principal | - |
Ausbildung von Jeff T. Hutchins
| Oral Roberts University | Undergraduate Degree |
| The University of Texas Health Science Center at Houston | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| AVID BIOSERVICES, INC. | Health Technology |
| SCORPIUS HOLDINGS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | Health Technology |
| Glaxo Wellcome, Inc. | Health Technology |
Pelican Therapeutics, Inc.
Pelican Therapeutics, Inc. Hospital/Nursing ManagementHealth Services Pelican Therapeutics, Inc. operates as an immuno-oncology company. It develops biological agents that represents the next generation of tumor necrosis factor (TNF) based immunotherapy. The company was founded by Jeffrey Wolf and Josiah C. Hornblower on March 6, 2017 and is headquartered in Dallas, TX. | Health Services |
